Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007). Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. American Society for Clinical Investigation.

Shah, Neil P., Brian J. Skaggs, Susan Branford, Timothy P. Hughes, John M. Nicoll, Ronald L. Paquette, och Charles L. Sawyers. Sequential ABL Kinase Inhibitor Therapy Selects for Compound Drug-resistant BCR-ABL Mutations With Altered Oncogenic Potency. American Society for Clinical Investigation, 2007.

Shah, Neil P., et al. Sequential ABL Kinase Inhibitor Therapy Selects for Compound Drug-resistant BCR-ABL Mutations With Altered Oncogenic Potency. American Society for Clinical Investigation, 2007.